Drugs / Gallium-68 labeled PSMA-HBED-CC
Gallium-68 labeled PSMA-HBED-CC
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04402151 Background | Jun 2020 → Dec 2027 expected | prostate cancer | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gallium-68 labeled PSMA-HBED-CC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04402151 ↗ |
| Modality | Diagnostic / imaging agent | “PSMA PET/MR is a novel imaging modality” NCT04402151 ↗ |
| Route | Intravenous | “PSMA tracer is administered by IV injection” NCT04402151 ↗ |